Hemostemix (CVE:HEM) Stock Price Up 27.8% – Still a Buy?

Hemostemix Inc. (CVE:HEM)’s stock price was up 27.8% during trading on Saturday . The company traded as high as C$0.12 and last traded at C$0.12. Approximately 335,071 shares traded hands during trading, a decline of 31% from the average daily volume of 486,759 shares. The stock had previously closed at C$0.09.

Hemostemix Trading Up 27.8%

The company has a market cap of C$16.76 million, a price-to-earnings ratio of -3.35 and a beta of 0.20. The business’s fifty day moving average price is C$0.10 and its 200 day moving average price is C$0.14. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48.

Insider Transactions at Hemostemix

In other news, Director Peter Alan Lacey bought 200,000 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The shares were acquired at an average price of C$0.15 per share, for a total transaction of C$30,000.00. 10.43% of the stock is owned by company insiders.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.